Tematropium
CAS No. 113932-41-5
Tematropium( CDDD3602 | HGP6 | Tematropium metilsulfate )
Catalog No. M26098 CAS No. 113932-41-5
Tematropium (CDDD3602) is an anticholinergic.
Purity : >98% (HPLC)
Size | Price / USD | Stock | Quantity |
2MG | 447 | Get Quote |
|
5MG | 709 | Get Quote |
|
10MG | 972 | Get Quote |
|
25MG | 1467 | Get Quote |
|
50MG | 1971 | Get Quote |
|
100MG | 2682 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTematropium
-
NoteResearch use only, not for human use.
-
Brief DescriptionTematropium (CDDD3602) is an anticholinergic.
-
DescriptionTematropium (CDDD3602) is an anticholinergic.
-
In Vitro——
-
In Vivo——
-
SynonymsCDDD3602 | HGP6 | Tematropium metilsulfate
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number113932-41-5
-
Formula Weight457.54
-
Molecular FormulaC21H31NO8S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (546.40 mM)
-
SMILESCOS([O-])(=O)=O.CCOC(=O)C(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
2-Hydroxy-3-methylbu...
2-Hydroxy-3-methylbutyric acid (2-hydroxyisovaleric acid) is a metabolite found in the urine of patients with phenylketonuria methylmalonic acidemia propionic acidemia 3-ketothiolase deficiency isovaleric acidemia 3-methylcrotonylglycemia 3-hydroxy-3-methylglutaric acidemia multiple carboxylase deficiency glutaric aciduria ornithine transcarbamylase deficiency glyceroluria tyrosinemia type I galactosemia and maple syrup urine disease.
-
Mahanimbine
Mahanimbine is found in the roots, leaves and stems of Murraya koenigii and is an orally active alkaloid extracted from Murraya koenigii.
-
Euchrestaflavanone B
Euchrestaflavanone B shows antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus. Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of protein kinase CKII activity.